Financials · RDHL

Redhill Biopharma Ltd. (RDHL) financials

For fiscal 2025 (ended Dec 31, 2025), Redhill Biopharma Ltd. reported $286.0K of revenue and -$429.0K of net income.

Revenue, FY2025
$286.0K
Revenue growth, YoY
-96.4%
Net income, FY2025
-$429.0K
Net margin
-150.0%
Free cash flow, FY2025
-$9.66M
EPS, diluted, FY2025
$0.00
Cash
$3.97M
P/S
10.88
Market cap
$3.1M
Annual revenue$286.0K
FY2016FY2025
Annual net income-$429.0K
FY2016FY2025
Annual free cash flow-$9.66M
FY2016FY2025

RDHL revenue and earnings growth

RDHL revenueFY2025$286.0K

FY YoY
-96.4%
5Y CAGR
-66.2%
10Y CAGR
+57.7%

RDHL revenue was $286.0K for fiscal 2025 (ended Dec 31, 2025), down 96.4% from fiscal 2024. Compound annual growth was -66.2% over 5 years and +57.7% over 10 years. It rose in 6 of the last 10 fiscal years.

RDHL net incomeFY2025-$429.0K

RDHL net income was -$429.0K for fiscal 2025 (ended Dec 31, 2025), compared with -$8.27M in fiscal 2024.

RDHL EPSFY2025$0.00

RDHL diluted EPS was $0.00 for fiscal 2025 (ended Dec 31, 2025).

RDHL free cash flowFY2025-$9.66M

RDHL free cash flow was -$9.66M for fiscal 2025 (ended Dec 31, 2025), compared with -$9.38M in fiscal 2024.

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$286.0K$8.04M$6.53M$61.80M$85.76M$64.36M$6.29M$8.36M$4.01M$101.0K
Cost of revenue-$3.19M$3.46M$33.34M$49.41M$36.89M$2.26M$2.84M$2.13M-
Gross profit-$4.85M$3.07M$28.46M$36.35M$27.47M$4.03M$5.52M$1.88M$101.0K
Research and development$2.02M$1.59M$3.53M$7.28M$29.50M$16.49M$17.42M$24.86M$32.97M$25.24M
Selling, general and admin$6.17M$4.89M$6.02M$28.59M$32.37M$25.38M$11.48M$7.51M$8.03M$3.85M
Operating income-$7.94M-$6.47M-$9.55M-$42.84M-$81.14M-$63.68M-$43.20M-$39.33M-$51.97M-$30.54M
Interest expense$1.46M$1.51M$9.25M$42.39M$16.66M$12.76M$438.0K$167.0K$77.0K$375.0K
Net income-$429.0K-$8.27M$23.92M-$71.67M-$97.74M-$76.17M-$42.30M-$38.82M-$45.54M-$29.37M
EPS, basic$0.00$0.00$0.01-$0.12-$0.21-$0.21-$0.14-$0.17-$0.26-$0.23
EPS, diluted$0.00$0.00$0.01-$0.12-$0.21-$0.21-$0.14-$0.17-$0.26-$0.24
Diluted shares31.59B12.32B2.59B616.3M465.3M364.3M296.9M231.2M176.6M128.8M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$3.97M$4.62M$5.57M$19.97M$29.47M$29.30M$29.02M$29.00M$16.45M$53.79M
Receivables-$2.54M$2.59M$34.52M$31.68M$28.66M$1.22M$958.0K$1.53M$99.0K
Inventory-$3.65M$4.39M$11.01M$14.81M$6.53M$1.88M$769.0K$653.0K-
Current assets$6.53M$11.91M$16.14M$85.90M$89.15M$70.50M$53.21M$56.79M$51.68M$67.81M
Total assets$25.34M$18.04M$23.05M$158.87M$181.19M$180.24M$74.10M$62.41M$57.34M$74.21M
Current liabilities$19.22M$22.22M$19.98M$197.45M$81.47M$73.23M$10.62M$10.38M$11.83M$5.36M
Long-term debt----$83.62M$81.39M----
Total debt----$83.62M$81.39M----
Total liabilities$21.08M$22.73M$20.98M$207.27M$172.31M$166.38M$14.10M$11.22M$12.28M$11.51M
Shareholders' equity$4.27M-$4.68M$2.07M-$48.40M$8.88M$13.86M$60.00M$51.19M$45.06M$62.70M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$9.65M-$9.37M-$35.82M-$29.18M-$65.05M-$48.58M-$40.75M-$34.46M-$44.77M-$28.26M
Capital expenditures$5.0K$9.0K$11.0K$198.0K$115.0K$406.0K$168.0K$23.0K$146.0K$85.0K
Free cash flow-$9.66M-$9.38M-$35.83M-$29.38M-$65.16M-$48.98M-$40.92M-$34.48M-$44.91M-$28.34M
Investing cash flow$1.69M-$9.0K$4.0K$8.30M-$8.14M-$35.65M$5.16M$5.35M-$18.58M$24.47M
Financing cash flow$7.32M$8.42M$21.44M$11.45M$73.46M$84.37M$35.51M$41.76M$25.65M$36.02M
Stock-based compensation$457.0K$665.0K$1.65M$5.67M$10.21M$4.20M$3.03M$2.68M$2.23M$1.68M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY-96.4%23.2%-89.4%-27.9%33.2%923.0%-24.7%108.6%3867.3%3266.7%
Gross margin-60.3%47.0%46.1%42.4%42.7%64.1%66.1%46.9%100.0%
Operating margin-2776.9%-80.5%-146.2%-69.3%-94.6%-99.0%-686.7%-470.5%-1297.0%-30240.6%
Net margin-150.0%-102.8%366.2%-116.0%-114.0%-118.4%-672.5%-464.4%-1136.6%-29079.2%
Free cash flow margin-3376.2%-116.6%-548.7%-47.5%-76.0%-76.1%-650.4%-412.5%-1120.9%-28062.4%
Return on equity-10.1%-1155.9%--1101.3%-549.4%-70.5%-75.8%-101.1%-46.8%
Return on assets-1.7%-45.8%103.8%-45.1%-53.9%-42.3%-57.1%-62.2%-79.4%-39.6%
Current ratio0.340.540.810.441.090.965.015.474.3712.66
Debt to equity----9.425.87----

Source: XBRL data Redhill Biopharma Ltd. files with the SEC, latest filing dated Apr 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.

RDHL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RDHL$286.0K-96.4%-$429.0K-150.0%$3.1M
IRWD$400.30M+18.1%$149.63M37.4%$791.3M
ARDX$468.22M+17.6%-$55.47M-11.8%$784.3M
PHAT$274.88M+86.8%-$83.00M-30.2%$430.8M
VNDA$229.28M+8.1%-$274.83M-119.9%$226.8M
ENTX$0-100.0%-$29.43M-$567.7M

RDHL FAQ

8 questions
  • What is RDHL revenue?
    Redhill Biopharma Ltd. (RDHL) reported $286.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 96.4% from the year before.
  • Is RDHL profitable?
    No. Redhill Biopharma Ltd. reported a net loss of $429.0K for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does RDHL have?
    Redhill Biopharma Ltd. reported $3.97M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is RDHL revenue growing?
    Redhill Biopharma Ltd.'s revenue changed -96.4% in fiscal 2025, to $286.0K. Its compound annual growth rate was -66.2% over 5 years and +57.7% over 10 years.
  • What is RDHL free cash flow?
    Redhill Biopharma Ltd. generated -$9.66M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$9.65M less capital expenditures.
  • What is RDHL earnings per share?
    Diluted earnings per share were $0.00 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did RDHL last report financial results?
    The latest statements here come from Redhill Biopharma Ltd.'s 20-F filed on Apr 27, 2026, covering the period ended Dec 31, 2025.
  • Where does this RDHL financial data come from?
    Quantisnow builds these statements from the structured XBRL data Redhill Biopharma Ltd. files with the SEC. It is provided for information only and is not investment advice.